NCT06946667

Brief Summary

The combined detection of HBP, ADPN, NGAL, and hs-CRP enables the construction of a highly efficient diagnostic model, offering a novel strategy for early infection identification and risk stratification after surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 9, 2021

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 10, 2024

Completed
21 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

April 6, 2025

Completed
21 days until next milestone

First Posted

Study publicly available on registry

April 27, 2025

Completed
Last Updated

April 27, 2025

Status Verified

January 1, 2025

Enrollment Period

3.8 years

First QC Date

April 6, 2025

Last Update Submit

April 20, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pathogen Resistance Characteristics and Development of a Combined Diagnostic Model Using hs-CRP, HBP, NGAL, and ADPN for Postoperative Urinary Tract Infections in Patients with Kidney Stones

    Postoperative UTI in kidney stone patients are primarily caused by Gram-negative bacteria with high resistance. Combined detection of hs-CRP, HBP, NGAL, and ADPN significantly improves diagnostic accuracy. HBP, NGAL, and ADPN serve as early predictive markers for postoperative infection, providing a reference for clinical practice.

    10 weeks

Study Arms (2)

the UTI group

Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.

Other: the UTI group

the Non-UTI group

Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.

Other: the Non-UTI group

Interventions

Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.

the UTI group

Laboratory parameters, including WBC, NLR, NEU, hs-CRP, HBP, NGAL, and ADPN levels, were measured. Midstream clean-catch urine samples from patients in the UTI group were collected for pathogen identification and antimicrobial susceptibility testing.

the Non-UTI group

Eligibility Criteria

Age44 Years - 62 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

A total of 130 patients diagnosed with kidney stones and treated at our hospital between February 2021 and December 2024 were enrolled in this study. Based on the presence of postoperative UTI, patients were categorized into the UTI group (n=41) and the Non-UTI group (n=89). The mean age of patients in the UTI group was 52.76±8.49 years, comprising 24 males and 17 females, whereas the Non-UTI group had a mean age of 53.03±7.12 years, including 43 males and 46 females.

You may qualify if:

  • Age ≥18 years;
  • Diagnosis of urinary calculi confirmed by CT, X-ray, or ultrasound;
  • Complete clinical data available. -

You may not qualify if:

  • Presence of active UTI or other infections prior to surgery;
  • Coexisting urological disorders (e.g., bladder cancer, neurogenic bladder);
  • Prolonged use of immunosuppressants or antibiotics (\>2 weeks). -

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Suzhou Hospital of Integrated Traditional Chinese and Western Medicine

Suzhou, Jiangsu, 215101, China

Location

MeSH Terms

Conditions

Kidney Calculi

Condition Hierarchy (Ancestors)

NephrolithiasisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisUrinary CalculiMale Urogenital DiseasesCalculiPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 6, 2025

First Posted

April 27, 2025

Study Start

February 9, 2021

Primary Completion

December 10, 2024

Study Completion

December 31, 2024

Last Updated

April 27, 2025

Record last verified: 2025-01

Locations